<div>COVID-19, an infectious disease caused by the SARS-CoV-2 virus, was declared a pandemic by the World Health Organisation (WHO) in March 2020. At the time of writing, more than 2.8 million people have tested positive. Infections have been growing exponentially and tremendous efforts are being made to fight the disease. In this paper, we attempt to systematise ongoing data science activities in this area. As well as reviewing the rapidly growing body of recent research, we survey public datasets and repositories that can be used for further work to track COVID-19 spread and mitigation strategies.</div><div>As part of this, we present a bibliometric analysis of the papers produced in this short span of time. Finally, building on these insights, we highlight common challenges and pitfalls observed across the surveyed works.</div>

<div>COVID-19, an infectious disease caused by the SARS-CoV-2 virus, was declared a pandemic by the World Health Organisation (WHO) in March 2020. At the time of writing, more than 2.8 million people have tested positive. Infections have been growing exponentially and tremendous efforts are being made to fight the disease. In this paper, we attempt to systematise ongoing data science activities in this area. As well as reviewing the rapidly growing body of recent research, we survey public datasets and repositories that can be used for further work to track COVID-19 spread and mitigation strategies.</div><div>As part of this, we present a bibliometric analysis of the papers produced in this short span of time. Finally, building on these insights, we highlight common challenges and pitfalls observed across the surveyed works.</div>

ChatGPT has recently been shown to pass the United States Medical Licensing Examination (USMLE). We tested ChatGPT (Feb 13, 2023 release) using a typical clinical toxicology case of acute organophosphate poisoning. ChatGPT fared well in answering all of our queries regarding it.

Health digital twins (HDTs) are virtual representations of real individuals that can be used to simulate human physiology, disease, and drug effects. HDTs can be used to improve drug discovery and development by providing a data-driven approach to inform target selection, drug delivery, and design of clinical trials. HDTs also offer new applications into precision therapies and clinical decision making. The deployment of HDTs at scale could bring a precision approach to public health monitoring and intervention. Next steps include challenges such as addressing socioeconomic barriers and ensuring the representativeness of the technology based on the training and validation data sets. Governance and regulation of HDT technology is still in the early stages. Expected final online publication date for the Annual Review of Pharmacology and Toxicology, Volume 64 is January 2024. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

About 1.2 million people in Europe have Parkinson's disease (PD). PD patients often suffer from social exclusion and depression due to progressive lack of control over the disease. Eventually, most require constant care, leading to huge socioeconomic burdens. To partially tackle this issue, 7 partners in 7 countries participated in LiveWell (EU-funded project, 2012-14) to develop an innovative Web-based education, training and social community platform targeting PD patients, carers and clinicians. This paper describes LiveWell from conception to completion, presents lessons learnt over the course of the project, and highlights some identified main areas of best practice. The Project Consortium might not have had the chance to implement everything learnt in the current outputs, but these lessons and guidelines can be later used to improve LiveWell, and can also be generalised to benefit similar e-health services. The combination of appropriate online education and social communities could help patients and carers cope positively with PD, promoting social inclusion and better outcomes.